A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report

Podobne zapisy

• Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
  od: Kuemmerle-Deschner, Jasmin B., i wsp.
  Wydane: (2013)
• Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
  od: Welzel, Tatjana, i wsp.
  Wydane: (2021)
• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  od: Kuemmerle-Deschner, J, i wsp.
  Wydane: (2015)
• Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes
  od: Ballbach, Marlene, i wsp.
  Wydane: (2016)
• Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
  od: Kuemmerle-Deschner, Jasmin B, i wsp.
  Wydane: (2011)